Compounded GLP-1 Drugs Persist Post-Shortage, Study Finds

Compounded versions of popular GLP-1 weight-loss drugs are still widely available even after the official shortage of brand-name semaglutide and tirzepatide ended. This finding comes from a secret shopper study of clinics in two U.S. States.

When the U.S. Food and Drug Administration (FDA) declares a drug shortage, compounding pharmacies are permitted to make direct copies. Researchers Michael J. DiStefano, PhD, and colleagues hypothesized that compounders would continue producing these medications with added ingredients after the shortage resolved. To test this, they conducted a cross-sectional study in West Virginia and Oklahoma.

Study Methodology and Scope

A researcher posed as a customer interested in weight loss, contacting brick-and-mortar weight-loss clinics and medical spas. The caller inquired about compounded GLP-1 receptor agonists, asking specific questions about added ingredients, treatment requirements, and costs. The study aimed to map the post-shortage market in states with potentially high demand for these drugs.

The research focused on two states where obesity rates are raise, suggesting strong demand for weight-loss medications. The secret shopper approach allowed the team to gather data on real-world business practices directly from providers.

Key Findings on Availability and Ingredients

The investigation found a strong market for compounded GLP-1 drugs. Many clinics offered these medications with added ingredients not found in the FDA-approved versions. Common additions included vitamins like B12, amino acids such as L-carnitine, and other substances.

Importantly, the availability persisted despite the fact that the FDA's shortage declaration for the brand-name drugs had ended. This means pharmacies are compounding these drugs outside the original regulatory exception created for shortages.

Details on Treatment and Cost

The secret shopper calls also gathered information on treatment protocols and pricing. Clinics typically required an initial consultation, often conducted virtually. Patients were then prescribed the compounded medication, which was usually shipped directly to them.

Costs varied between providers. The study did not provide a comparative table of exact prices, as figures were not uniformly reported across all clinics contacted. However, the researchers noted that prices were frequently lower than those for branded GLP-1 drugs.

Regulatory and Safety Implications

The continued production of these compounded drugs raises significant regulatory questions. The FDA permits compounding only during a declared shortage or when a pharmacist creates a tailored medication for an individual patient based on a prescription. The widespread commercial availability described in the study may fall outside these guidelines.

Safety concerns are most important. Compounded drugs are not evaluated by the FDA for safety, quality, or efficacy. Adding ingredients like B12 or L-carnitine creates a new formulation whose effects are not studied. Researchers and the source article link this practice to potential patient risks.

The study's authors conclude that their findings highlight a persistent market for compounded GLP-1 agonists. They suggest this warrants further regulatory scrutiny to ensure patient safety.